Testing effectiveness (Phase 2)WithdrawnNCT00824811What this trial is testingTopical Cyclosporine vs. Placebo for Epiphora Associated With DocetaxelWho this might be right forEpiphora M.D. Anderson Cancer Center
Not applicableStudy completedNCT00408681What this trial is testingLithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+111 more Fred Hutchinson Cancer Center 20
Testing effectiveness (Phase 2)Ended earlyNCT04408599What this trial is testingA Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid TumorsWho this might be right forAdvanced or Metastatic Solid TumorsOvarian CancerGastric Cancer+1 more NextCure, Inc. 46
Early research (Phase 1)Study completedNCT02737787What this trial is testingA Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian CancerWho this might be right forOvarian CancerFallopian TubePrimary Peritoneal Cancer+1 more Memorial Sloan Kettering Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT03345485What this trial is testingStudy of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.Who this might be right forSmall Cell Lung CancerSoft Tissue SarcomaTriple-negative Breast Cancer+2 more Mundipharma Research Limited 71
Early research (Phase 1)Looking for participantsNCT06756035What this trial is testingCT-95 in Advanced Cancers Associated With Mesothelin ExpressionWho this might be right forMesothelin-Expressing TumorsEpithelial Ovarian CancerMalignant Pleural Mesothelioma, Advanced+8 more Context Therapeutics Inc. 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT03660826What this trial is testingTesting the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneWho this might be right forEndometrial AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous Adenocarcinoma+3 more National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT03219268What this trial is testingMGD013 in Patients With Unresectable or Metastatic NeoplasmsWho this might be right forAdvanced Solid TumorsHematologic NeoplasmsOvarian Cancer+7 more MacroGenics 277
Early research (Phase 1)Study completedNCT00003548What this trial is testingAminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal CavityWho this might be right forCancer NYU Langone Health 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06792435What this trial is testingXNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Who this might be right forPancreatic Adenocarcinoma MetastaticLung Cancer (NSCLC)Ovarian Cancer+4 more Astellas Pharma Global Development, Inc. 240
Testing effectiveness (Phase 2)Study completedNCT00003308What this trial is testingRadiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or SarcomaWho this might be right forKidney CancerMelanoma (Skin)Metastatic Cancer+2 more Eastern Cooperative Oncology Group
Early research (Phase 1)Ended earlyNCT02837991What this trial is testingA Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell CarcinomaWho this might be right forRenal Cell Carcinoma (RCC)Clear-cell Renal Cell CarcinomaPapillary Renal Cell Carcinoma+3 more Celldex Therapeutics 16
Testing effectiveness (Phase 2)UnknownNCT00410462What this trial is testingBrostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue SarcomaWho this might be right forOvarian CancerSarcomaSmall Intestine Cancer European Organisation for Research and Treatment of Cancer - EORTC 118
Early research (Phase 1)Study completedNCT06108479What this trial is testingStudy of DF6215 in Patients With Advanced Solid TumorsWho this might be right forSolid Tumor, AdultSolid Tumor Cancer Dragonfly Therapeutics 35
Not applicableLooking for participantsNCT05236686What this trial is testingSurvival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian CancerWho this might be right forEpithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma Shanghai Gynecologic Oncology Group 94
Early research (Phase 1)Looking for participantsNCT05746897What this trial is testingA First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid TumorsWho this might be right forOvarian CancerMelanomaTriple Negative Breast Cancer+1 more Hefei TG ImmunoPharma Co., Ltd. 38
Early research (Phase 1)Study completedNCT00635596What this trial is testingPhase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian CancerWho this might be right forSolid Tumors Amgen Research (Munich) GmbH 65
Early research (Phase 1)Study completedNCT02222922What this trial is testingPF-06647020 For Adult Patients With Advanced Solid TumorsWho this might be right forNeoplasms Pfizer 138
Early research (Phase 1)Looking for participantsNCT06586957What this trial is testingA Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsWho this might be right forSolid TumorAdvanced Solid TumorSolid Tumor, Adult+25 more NiKang Therapeutics, Inc. 150
Testing effectiveness (Phase 2)Looking for participantsNCT06128551What this trial is testingStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsWho this might be right forNon-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma Revolution Medicines, Inc. 534